BioSpace News Archive

Kite announced that Fosun Kite Biotechnology Co., Ltd., has received approval from the China National Medical Products Administration for axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

The global enzymatic debridement market is anticipated to grow at a healthy rate over the forecast period.

Photocure, The Bladder Cancer Company, announces the publication of a study in the journal Urologic Oncology.

Abivax SA announces excellent top-line results of the induction phase of its phase 2a clinical study of ABX464 administered in combination with methotrexate for the treatment of active moderate to severe rheumatoid arthritis.

Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, announced the closing of a USD 17.5 million financing, led by Petrichor Healthcare Capital Management, with participation from existing Leukocare shareholders.

BioSpace, the leader in biopharma news and careers has published it’s 2021 U.S. Life Sciences Salary Report.

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease and other neurodegenerative disorders, announced that it has achieved enrollment target of 80 patients for its Phase 2 biomarker study of ALZ-801 in Early AD patients, who carry either one or two copies of the ε4 allele of apolipoprotein E gene.

Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic central nervous system disorders, announced that it has successfully completed a microdose study in healthy volunteers under an exploratory IND approved by FDA in January 2021.

Dante Labs, a leading genomics and diagnostics company, announced the acquisition of Cambridge Cancer Genomics, a groundbreaking Y-Combinator company & leader in machine learning for clinical oncology, to create a single platform with unparalleled capabilities in genomics and oncology data analysis.

SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, presented preclinical regenerative medicine data showing that the company’s Cell Squeeze® technology can be used to generate neurons from induced human pluripotent stem cells through the single delivery of an mRNA encoding fate-specifying transcription factor.